BMC Medical Genetics

Table 1 Clinico-pathological characteristics of the study group

From: Matrix Metalloproteinase-9 (MMP-9) polymorphisms in patients with cutaneous malignant melanoma

Variable	Patients	%
*Gender*
Males	573	57.2
Females	429	42.8
*Family History*
Yes	167	16.7
No	826	82.4
Unknown	9	0.9
*Multi-primary Melanoma*
Yes	152	15.2
No	849	84.7
Unknown	1	0.1
*Stage at Diagnosis*
0	58	5.8
I	504	50.3
II	235	23.4
III	169	16.9
IV	9	0.9
Unstagable^¥	27	2.7
*Current Stage*
0	56	5.6
I	435	43.4
II	159	15.9
III	217	21.7
IV	129	12.9
Unstagable^¥	6	0.5
*Primary Clark Level*
I	58	5.8
II	108	10.8
III	150	14.9
IV	489	48.8
V	69	6.9
Unknown	128	12.8
*Thickness (mm)*
In situ	58	5.8
< 1.01	321	32.0
1.01 – 2.00	272	27.1
2.01 – 4.00	161	16.1
> 4.00	121	12.1
Unknown	69	6.9
*Distant Metastasis*
Yes	130	13.0
No	870	86.8
N/A^φ	2	0.2
*Phenotypic Index*
1 (low risk)	38	3.8
2	210	21.0
3	317	31.6
4	328	32.7
5 (high risk)	105	10.5
N/A^φ	4	0.4
*Site of the Primary Melanoma*
Extremities	535	53.4
Trunk	342	34.1
Head and Neck	71	7.1
Non-cutaneous^ω	12	1.2
Unknown	42	4.2

^¥due to missing data on the "T" classification
^φN/A: not available
^ω90% mucosal melanomas and 10% other sites.

Back to article page

ISSN: 1471-2350

Contact us

General enquiries: ORSupport@springernature.com